Log In
Tuesday 27th June 2017

NICE backs breast cancer drug

23rd November 2006

NICE has approved a new class of drugs in the treatment of older women with breast cancer.

The aromatase inhibitors (AIs) will now be available to treat women with hormone-sensitive tumours.

The approval brings the UK into line with most other European countries where the drugs have become standard treatment.

Professor Jeffrey Tobias of University College London said evidence shows the inhibitors work better than tamoxifen in reducing the chances of a recurrence of the disease.

The AIs work by suppressing production of oestrogen, which has been linked to breast cancer in post-menopausal women.

The decision is expected to affect around 23,000 women with newly diagnosed breast cancer and other patients already taking tamoxifen.

More than 40,000 women in the country are diagnosed with breast cancer each year.

Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2017